We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Microfluidics Enables Reliable siRNA Drug Delivery for Inflammatory Diseases and Tumor Targeting
Product News

Microfluidics Enables Reliable siRNA Drug Delivery for Inflammatory Diseases and Tumor Targeting

Microfluidics Enables Reliable siRNA Drug Delivery for Inflammatory Diseases and Tumor Targeting
Product News

Microfluidics Enables Reliable siRNA Drug Delivery for Inflammatory Diseases and Tumor Targeting


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Microfluidics Enables Reliable siRNA Drug Delivery for Inflammatory Diseases and Tumor Targeting"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Researchers in the Department of Pharmacy at the Ludwig Maximilian University of Munich are using chips from Dolomite Microfluidics to reliably and consistently produce monodisperse particles for targeted delivery of small interfering RNA (siRNA) therapeutics. This microfluidic encapsulation technology is ideal for gene silencing applications in cancer immunology and inflammatory diseases, where siRNA can potentially be used to down-regulate genes associated with these pathologies.

Prof. Dr. Olivia Merkel, Professor of Drug Delivery, explained: “Nanoencapsulation is a highly efficient way to deliver siRNA to targets across the cellular membrane, protecting it from degradation prior to endocytosis. It is important to deliver the therapy in a controlled and reproducible manner; the particle size has a huge impact on in vivo work, affecting the rate of uptake and clearance.”

“Previously, we produced our nanoparticles manually, which was both time consuming and uncontrolled, and resulted in a range of particle diameters. We needed a solution to overcome this challenge and, in 2017, discovered Dolomite Microfluidics. We’ve been using Dolomite chips ever since, consistently downsizing our particles from around 200 to 100 nanometers and below. Our batch-to-batch reproducibility has improved immensely, and we are confident that the nanoparticles we prepare will have low polydispersity and be the optimal size for our work, which is important. We are very pleased with what we have achieved so far using the Dolomite chips, and are excited about what we still have to come.”

Advertisement